{"nctId":"NCT02096861","briefTitle":"Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease","startDateStruct":{"date":"2014-09-19","type":"ACTUAL"},"conditions":["Crohn's Disease"],"count":220,"armGroups":[{"label":"CT-P13 - CT-P13","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P13"]},{"label":"CT-P13 - Remicade","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: CT-P13","Biological: Remicade"]},{"label":"Remicade - Remicade","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Remicade"]},{"label":"Remicade - CT-P13","type":"EXPERIMENTAL","interventionNames":["Biological: CT-P13","Biological: Remicade"]}],"interventions":[{"name":"CT-P13","otherNames":[]},{"name":"Remicade","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients with active Crohn's disease and a Crohn's disease activity index score between 220 and 450 points\n\nExclusion Criteria:\n\n* Patient who has previously received a biological agent for the treatment of Crohn's disease and/or a Tumor necrosis factor (TNF)-alpha inhibitor for the treatment of other disease.\n* Patient who has allergies to any of the excipients of infliximab, any other murine and/or human proteins, or patient with a hypersensitivity to immunoglobulin product.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number and Percentage of Patients Achieving Clinical Response According to Crohn's Disease Activity Index (CDAI)-70 Criteria at Week 6","description":"A patient was defined as having a CDAI-70 response if there was a decrease in CDAI score of 70 points or more at Week 6 comparing to the baseline value.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients Achieving Clinical Response According to CDAI-70 Criteria at Week 30","description":"A patient was defined as having a CDAI-70 response if there was a decrease in CDAI score of 70 points or more from the baseline value.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients Achieving Clinical Response According to CDAI-70 Criteria at Week 54","description":"A patient was defined as having a CDAI-70 response if there was a decrease in CDAI score of 70 points or more from the baseline value.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients Achieving Clinical Remission at Week 6","description":"Clinical remission was defined as an absolute CDAI score of less than 150 points.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients Achieving Clinical Remission at Week 30","description":"Clinical remission was defined as an absolute CDAI score of less than 150 points.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number and Percentage of Patients Achieving Clinical Remission at Week 54","description":"Clinical remission was defined as an absolute CDAI score of less than 150 points.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)","description":"SIBDQ is scored with 10 sub-question which can be scored from 1 to 7. Therefore, SIBDQ can be scored from 7 to 70.\n\nHigher values of SIBDQ represent a better patient disease outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":"10.92"},{"groupId":"OG001","value":"33.9","spread":"9.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":"10.86"},{"groupId":"OG001","value":"45.8","spread":"12.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":"11.96"},{"groupId":"OG001","value":"52.5","spread":"10.68"}]}]}]},{"type":"SECONDARY","title":"The Short Inflammatory Bowel Disease Questionnaire","description":"SIBDQ is scored with 10 sub-question which can be scored from 1 to 7. Therefore, SIBDQ can be scored from 7 to 70.\n\nHigher values of SIBDQ represent a better patient disease outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":"10.61"},{"groupId":"OG001","value":"33.8","spread":"11.31"},{"groupId":"OG002","value":"33.3","spread":"9.77"},{"groupId":"OG003","value":"34.5","spread":"8.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":"10.28"},{"groupId":"OG001","value":"54.1","spread":"11.07"},{"groupId":"OG002","value":"52.6","spread":"11.35"},{"groupId":"OG003","value":"51.2","spread":"11.26"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":56},"commonTop":["Abdominal pain","Anaemia","Infusion-related reaction","Arthralgia","Influenza"]}}}